{"name":"NovelMed Therapeutics","slug":"novelmed-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQVWhCWllGZ1AtcFB4d2JBUmFPNUR0TmhnS3ZzN0N6VTRtTzd6MGxfSllEYXBDV0F4djAwdHFjUkNSWTVvS2d0QWRmTkdlbVJWYmtnUUVIOFFWMHN6ZWF3MTFNak12VVdNblpkYWdoSVBtbW03MUZucjM5WVdsVXJBWl85a1FiY3dxMFNWYUFoRDFWNEtEc005cmZlVDB3OVRsYmVsdzJnNTRTQ1hkMERaemYydDFVOGNKd25KUVIxOEppZkRrVkl0UlN6bVpfZ05SVjVjQWp3SVlYUjg2TDJGdlBwclJWd3U5MFlCM2pocUNBLUd4NlJoRzNGWkJvTldrdG9DUFVRMl9qSzVWQTRHQmMzcElCTDlCcnBjbEg2QVBfbTBkcFhleTA2M3lGV0dSaGJjZGIyc1NXRnRpT2VjaUFYU0c?oc=5","date":"2026-03-09","type":"regulatory","source":"GlobeNewswire","summary":"NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH - GlobeNewswire","headline":"NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intraven","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-22","type":"pipeline","source":"GlobeNewswire","summary":"Complement 3 Glomerulopathy Market Poised for Phenomenal - GlobeNewswire","headline":"Complement 3 Glomerulopathy Market Poised for Phenomenal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQd2wtajMzczNvQXQ2NHVPb1k5VVFJTHB6RnBwd01QWnZTbWtHT1V3R1EwSElhZVAtZkRnV1JwRzlUS1llZjlMTGVBbTN6cGJrWFI4SXVUSHd1WWdzekk0VzFHQ1o3ME53RThZQmZSNXdDZnZLZnhUSmlUcUx1aXk0UjhfbWVVTlZOWThWMlpXajRBc05hMnBEZnMweE55ekRxWEpXVnM3ZkJ5bmhzTGdYa0RGSkR4TmFzbjdfd2ZTYzhwa0NubHFLcGZKZ1NnVDc0RElkUDl2U3VGdEY1NnFPdG1kMC1YbGxFckc1R2dEOVFvdVpfbDk0?oc=5","date":"2025-10-22","type":"regulatory","source":"PR Newswire","summary":"Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight - PR Newswire","headline":"Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQMTJSZlNqYVZKNjI4U2tWRUtKSU1jQWcyN1dRcUwtVTBmMHI5TjJWb2YtMklvdVg4YmNDUG5sa1lobmFKQ1VCOHViLTJhUTBTeE9CcVc2eTl6SVdpUFJiOXNyWnRKZ2ZoZEx6Y2FnMm0zTWhHQkRPenMybFdWVmgwZlIyLUZwbExKTzFsZkhYQ2ZRc1haeGFMNVNlS0FUT2dORHRPTDdNQXZKcXBXdjdMYWptVVNSWkhaR2xoT0pGNURWcFFxT0VQYTJIN1V4NjlwbFNKaC1QdG1HZU1Za1JNd1dIWnRCNDViX3hIUmNNU1RIRGpUWU5RU3UtSmNaUVE3MG9rdkk1WDVaOEZjVTNZMEFYV3NzZ1ZBMFMtTXdydkQ4bVU?oc=5","date":"2025-02-24","type":"regulatory","source":"GlobeNewswire","summary":"United States FDA Approves NM8074 (Ruxoprubart) IND for - GlobeNewswire","headline":"United States FDA Approves NM8074 (Ruxoprubart) IND for","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQTFg5LVNKek5vbXpqTVB6eUtLLVdOTWJjRjdTeGF2SU9TRkZ0SFdjbk9vZ3lrX1dvYVh6NHAyWE14SC1PMEoyZnNjQ0Uzbm5lTGZxaHNpVTNJbXRhdFk0YzBFVFJLZlNDY1ZfVzNCUnhvVHl4M3JyMU5fcnhOV0g5bUlxZWlab3BFeFZBZTJmeWswUnBMV0FLR1hTM090TkhEVUxMNHU3QVFtNEloX3lUYWdCZEVxbjNIc3d5VjhkaEN4ZWk0Ui1kbEF0YVk2YkJYajNpem00UFdmdmh5MnY1MUF2MEpRbjBmVmRYcW9TbGd2RFhfdEhvZDVzX0V5RjhBOVZWWi1wQ1RuaDdvcTBGVURB?oc=5","date":"2025-02-20","type":"pipeline","source":"BioSpace","summary":"Atypical Hemolytic Uremic Syndrome Market Size Predicted to Grow at a Steady CAGR of 4.1% during 2025-2035, Impelled by Rising Incidence & Awareness - BioSpace","headline":"Atypical Hemolytic Uremic Syndrome Market Size Predicted to Grow at a Steady CAGR of 4.1% during 2025-2035, Impelled by ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQal85aXQzeWtTNzNUY055eHMxYXhidFFfNG1oUGhxdWV6T2IySEhXRHYzYUpFZDltR0FuVFBGRUJVYnI5UGFhVGFIZmxvX1ZrM1ZDVHBYaEZqR1l0ODZwTF9WaElWSGZ1c2JpelVhUDBtMXA3REZaOTVhYmVGY28yNnRtV3RaZVM2S3JsWkEtME1jVnY1N0E?oc=5","date":"2024-10-28","type":"trial","source":"Yahoo Finance","summary":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight - Yahoo Finance","headline":"Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxORTlScGVBamw1Z1hMSW5VRTJUYnk0WGh3Z0dwTVBKRUpPOVNTOFdjaFRiakZSRXI4dlM5RXUxOVMzcUJwX1RqVkQtR1Rnb2lhNFd2SGk1TmtpNk9kTXFPZE8tWlNRRXJnRUJHNjU0VXJuUzhIMEZLN1Q2VWRlVUFxdW4xd05yOTNzNm5JNEIyWGh2X2xLY1RIVW1GNEdVX0FBcVFMXzcxZ3pEWGhxTTRZTnE3WGVxdy12MFM5a1Bhb0pPU2hOT1c5Q0hCdFRTeVpoamxEdVViV0U4Wm9STGZ1NFdCZDFtTlV1N3lEOWRhb2FRZVZfOEdaRGVFTWQ5cG55N2E0?oc=5","date":"2024-08-21","type":"regulatory","source":"PR Newswire","summary":"Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNUW16LVRWdjBoZVBsWjI3WEpQQkFpZ0lJVW1iT01YU245MHBxYnI1WjlaSTg3M0xJLTExeFlYbmpyNVlTNmFVVmFYb0daTkJtbFdMVkZ3c2Fob2F0WVNZMnJnb01SZmZ0QnlsSnJZS3Zjc2RCOEt1NFpsSzRFYjlxNmcxRUNJUUZzU2JOQ3ozY0hCWHgzWk5xVXFueGtSMG1XUTNXTlM2MzB6RFdyMmxyVU9sd2dwbWxMTjB0VWs3bl9OZWNOT0lMQjUtVC14LWtzbnUyalJfazdxU19SeXZ6bDR2dmJqdzdveGZBV2p2ZHNvdjc1TXowd3VXZ1dhbE5veHhnOWE4VUg4M3c?oc=5","date":"2024-02-12","type":"regulatory","source":"GlobeNewswire","summary":"Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for - GlobeNewswire","headline":"Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}